Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316266 | 0.94 | MAPK14 (0.33) | KDM4EMAPTHPGDMAPK1NPSR1 | |
| SCHEMBL2318348 | 0.92 | MAPK1 (0.31) | MAPK1NPSR1BRAFHCRTR2 | |
| SCHEMBL2316375 | 0.89 | JMJD6 (0.33) | KDM4EMAPTHPGDMAPK1NPSR1 | |
| SCHEMBL14719372 | 0.89 | HCRTR2 (0.33) | HCRTR2 | |
| SCHEMBL17836543 | 0.88 | HCRTR2 (0.30) | MAPK1NPSR1HCRTR2 | |
| SCHEMBL2315677 | 0.86 | MAPK14 (0.34) | KDM4EMAPTHPGDMAPK1NPSR1 | |
| SCHEMBL14718464 | 0.86 | HCRTR2 (0.34) | KDM4EMAPK1NPSR1HCRTR2 | |
| SCHEMBL2315864 | 0.85 | PDE10A (0.34) | JMJD6 | |
| SCHEMBL2315357 | 0.85 | JMJD6 (0.33) | JMJD6BRAFCETP | |
| SCHEMBL2318341 | 0.84 | JMJD6 (0.41) | KDM4EMAPTHPGDJMJD6BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528909-B1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-06-22 | — | — | EP | claimed |
| US-8791265-B2 | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-29 | — | — | US | claimed |
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-02-28 | — | — | US | claimed |
| EP-2528909-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-12-05 | — | — | EP | claimed |
| WO-2011092088-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-08-04 | — | — | WO | claimed |
| EP-2528909-B1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-06-22 | — | — | EP | disclosed |
| US-8791265-B2 | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-29 | — | — | US | disclosed |
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-02-28 | — | — | US | disclosed |
| EP-2528909-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011092088-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K15, MAP3K19, CDK3 | KDM4E 1064/4885MAPT 1039/4885HPGD 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.